Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07283159

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07283159
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07283159. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-20 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)
Intervention (Drug)
Human Urinary Kallidinogenase
Lead sponsor
General Hospital of Shenyang Military Region (class: other)

Record details

Record id
cardio:ct-nct07283159
Content hash
8b10a49f5ce46ff46eb521fc232207ff5cad9034e40761abe001e8faec0e6cec